Modulation of immunologic responses to HIV-1 MN recombinant gp160 vaccine by dose and schedule of administration

By National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group   Gorse G.J.   McElrath M.J.   Matthews T.J.   Hsieh R.-H.   Belshe R.B.   Corey L.   Frey S.E.   Kennedy D.J.   Walker M.C.   Eibl M.M.  

Vaccine, Vol. 16, Iss. 5, 1998-03 ,pp. : 493-506

Elsevier

Access to resources Recommend Favorite

Immunization of mice with recombinant gp41 in a systemic prime/mucosal boost protocol induces HIV-1-specific serum IgG and secretory IgA antibodies

By Mantis N.J.   Kozlowski  

Vaccine, Vol. 19, Iss. 28, 2001-07 ,pp. : 3990-4001

Elsevier

Access to resources Recommend Favorite

Recombinant gp160 vaccination schedule and MHC HLA type as factors influencing cellular responses to HIV-1 envelope glycoprotein

By Gorse G.J.   Patel G.B.   Newman F.K.   Mandava M.   Belshe R.B.  

Vaccine, Vol. 13, Iss. 13, 1995-01 ,pp. : 1170-1179

Elsevier

Access to resources Recommend Favorite

Efficient purification and rigorous characterisation of a recombinant gp120 for HIV vaccine studies

By Jones D.H.   McBride B.W.   Roff M.A.   Farrar G.H.  

Vaccine, Vol. 13, Iss. 11, 1995-01 ,pp. : 991-999

Elsevier

Access to resources Recommend Favorite

Vaccine-induced antibodies to the native, oligomeric envelope glycoproteins of primary HIV-1 isolates

By Lee S.A.   Orque R.   Escarpe P.A.   Peterson M.L.   Good J.W.   Zaharias E.M.   Berman P.W.   Sheppard H.W.   Shibata R.  

Vaccine, Vol. 20, Iss. 3, 2001-11 ,pp. : 563-576

Elsevier

Access to resources Recommend Favorite